III期卵巢癌间歇性减瘤术联合HIPEC的成本效果分析:基于随机III期试验
基于OVHIPEC随机III期试验,构建Markov健康状态转换模型,从荷兰社会视角评估III期卵巢癌间歇性减瘤术联合腹腔热灌注化疗(HIPEC)的成本效果,时间跨度10年。结果显示联合HIPEC组QALY增益显著,增量成本效果比(ICER)为每QALY 28,299欧元,低于荷兰支付意愿阈值,提示该治疗具有成本效果。
要点
- 间歇性减瘤术联合HIPEC较单纯减瘤术增加QALY,ICER为28,299欧元/QALY。
- ICER低于荷兰支付意愿阈值,支持该治疗具有成本效果。
- 无复发生存效用值和住院天数是影响ICER的最主要参数。
核心结论
- 在III期卵巢癌患者中,间歇性减瘤术联合HIPEC带来显著的QALY增益,ICER为28,299欧元/QALY,低于荷兰支付意愿阈值,具有成本效果。
研究设计与样本
- 基于随机开放标签III期OVHIPEC试验数据,构建Markov健康状态转换模型,从荷兰社会视角评估10年时间跨度的成本与临床结局。
主要发现
- 间歇性减瘤术组总医疗成本为70,046欧元(95%可信区间64,016至76,661欧元),联合HIPEC组为85,791欧元(95%可信区间78,766至93,935欧元)。
- 间歇性减瘤术组平均QALY为2.12(95%可信区间1.66至2.64),联合HIPEC组为2.68(95%可信区间2.11至3.28)。
- 增量成本效果比(ICER)为28,299欧元/QALY。
- 单变量敏感性分析中,无复发生存效用值和住院天数对ICER影响最大。
关键数值与推荐
- ICER为28,299欧元/QALY,低于荷兰支付意愿阈值。
临床怎么用
- 在具有可比医疗体系的国家,结果为报销III期卵巢癌患者间歇性减瘤术联合HIPEC的治疗费用提供了额外支持。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
PURPOSE: In the randomized open-label phase III OVHIPEC trial, the addition of hyperthermic intraperitoneal chemotherapy (HIPEC) to interval cytoreductive surgery (CRS) improved recurrence-free and overall survival in patients with stage III ovarian cancer. We studied the cost effectiveness of the addition of HIPEC to interval CRS in patients with ovarian cancer. PATIENTS AND METHODS: We constructed a Markov health-state transition model to measure costs and clinical outcomes. Transition probabilities were derived from the OVHIPEC trial by fitting survival distributions. Incremental cost-effectiveness ratio (ICER), expressed as euros per quality-adjusted life-year (QALY), was calculated from a Dutch societal perspective, with a time horizon of 10 years. Univariable and probabilistic sensitivity analyses were conducted to evaluate the decision uncertainty. RESULTS: Total health care costs were €70,046 (95% credibility interval [CrI], €64,016 to €76,661) for interval CRS compared with €85,791 (95% CrI, €78,766 to €93,935) for interval CRS plus HIPEC. The mean QALY in the interval CRS group was 2.12 (95% CrI, 1.66 to 2.64 QALYs) and 2.68 (95% CrI, 2.11 to 3.28 QALYs) in the interval CRS plus HIPEC group. The ICER amounted to €28,299/QALY. In univariable sensitivity analysis, the utility of recurrence-free survival and the number of days in the hospital affected the calculated ICER most. CONCLUSION: On the basis of the trial data, treatment with interval CRS and HIPEC in patients with stage III ovarian cancer was accompanied by a substantial gain in QALYs. The ICER is below the willingness-to-pay threshold in the Netherlands, indicating interval CRS and HIPEC is cost effective for this patient population. These results lend additional support for reimbursing the costs of treating these patients with interval CRS and HIPEC in countries with comparable health care systems.
引用
- Koole SN, van Lieshout C, van Driel WJ, et al. Cost Effectiveness of Interval Cytoreductive Surgery With Hyperthermic Intraperitoneal Chemotherapy in Stage III Ovarian Cancer on the Basis of a Randomized Phase III Trial. J Clin Oncol. 2019. PMID: 31251694. doi:10.1200/JCO.19.00594
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。